Results 91 to 100 of about 13,861 (164)

FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer. [PDF]

Clin Cancer Res
Liu Y, Nashed J, Barone AK, Yuan M, Amatya AK, Xiang Y, Zhao H, Bi Y, Pegues MA, Miller CP, Lane AR, Mixter BD, Tang S, Pazdur R, de Claro RA, Larkins E.   +15 more
europepmc   +1 more source

Stability study of topotecan in ophthalmic prefilled syringes for intravitreal delivery. [PDF]

Eur J Hosp Pharm
Bello W, Hosotte C, Stampfli C, Pierrot A, Munier FL, Berger-Gryllaki M, Pezzatti J, Carrez L, Sadeghipour F.   +8 more
europepmc   +1 more source

Reply : Primary suspect drugs of cataracts in pediatric patients: FDA adverse events reporting database analysis. [PDF]

J Cataract Refract Surg
Khan SM, Abboud I, Elhusseiny AM, Elhusseiny AM.   +3 more
europepmc   +1 more source

Role of additional topotecan injections (plus two) in reducing recurrence rate in retinoblastoma of group D and group E patients: a retrospective study. [PDF]

BMJ Open Ophthalmol
Lin X, Zheng Z, Chen H, Qian J, Liu Q, Ma R, Xue K.   +6 more
europepmc   +1 more source

Comment on: Primary suspect drugs of cataracts in pediatric patients: FDA adverse events reporting database analysis. [PDF]

J Cataract Refract Surg
Rani T, Mandal R, Bandyopadhyay A.
europepmc   +1 more source

HIGH-DOSE INTRAVITREAL TOPOTECAN (100 µ G/0.1 CC) AS MONOTHERAPY FOR RECURRENT/REFRACTORY INTRAOCULAR RETINOBLASTOMA IN SEVEN EYES. [PDF]

Retina
Vempuluru VS, Raval V, Kaliki S.
europepmc   +1 more source

Place in therapy of key treatments for platinum-sensitive, relapsed, extensive-stage small cell lung cancer with a focus on lurbinectedin: a narrative review with case studies. [PDF]

Drugs Context
Shunyakov L, Badin FB, Hafer J, König D, Froesch P, Greillier L.   +5 more
europepmc   +1 more source

Quantitative high-throughput screening identifies small-molecule modulators of Wnt/β-catenin signaling. [PDF]

Front Pharmacol
Chen X, Yang S, Sakamuru S, Sukhawanit C, Wood S, Ooka M, Huang R, Xia M.   +7 more
europepmc   +1 more source

High-Risk neuroblastoma therapeutics Topotecan and 13-cis-Retinoic acid modulate autophagy and induce DNA damage response in hematopoietic stem cells and monocytes. [PDF]

Sci Rep
Lázničková P, Tidu F, Hrdý J, Boráková K, Hortová Kohoutková M, Frič J.   +5 more
europepmc   +1 more source

Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma. [PDF]

Sci Adv
Han JZR, Phimmachanh M, Hastings JF, Leong KH, Ng BH, Ni J, Fontaine-Titley A, Cadell AL, O'Donnell YE, Clearwater M, Kamili A, Haber M, Norris M, Timpson P, Trahair TN, Fletcher JI, Fey D, Kolch W, Latham SL, Croucher DR.   +19 more
europepmc   +1 more source